The extreme antigenic lability of the influenza A viruses accounts for the less-than-ideal immunization capability of existing vaccines; at the same time, as Dr. Kilbourne explains, this characteristic is making it possible to “breed” viral recombinants in the laboratory that will have the qualities (such as high yield and low virulence) needed to produce vaccines capable of conferring more lasting immunity.